首页> 外文OA文献 >Fumarase activity: an in vivo and in vitro biomarker for acute kidney injury:an in vivo and in vitro biomarker for acute kidney injury
【2h】

Fumarase activity: an in vivo and in vitro biomarker for acute kidney injury:an in vivo and in vitro biomarker for acute kidney injury

机译:富马酸酶活性:急性肾损伤的体内和体外生物标志物:急性肾损伤的体内和体外生物标志物

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Renal ischemia/reperfusion injury (IRI) is a leading cause of acute kidney injury (AKI), and at present, there is a lack of reliable biomarkers that can diagnose AKI and measure early progression because the commonly used methods cannot evaluate single-kidney IRI. Hyperpolarized [1,4-C-13(2)] fumarate conversion to [1,4-C-13(2)] malate by fumarase has been proposed as a measure of necrosis in rat tumor models and in chemically induced AKI rats. Here we show that the degradation of cell membranes in connection with necrosis leads to elevated fumarase activity in plasma and urine and secondly that hyperpolarized [1,4-C-13(2)] malate production 24 h after reperfusion correlates with renal necrosis in a 40-min unilateral ischemic rat model. Fumarase activity screening on bio-fluids can detect injury severity, in bilateral as well as unilateral AKI models, differentiating moderate and severe AKI as well as short-and long-term AKI. Furthermore after verification of renal injury by bio-fluid analysis the precise injury location can be monitored by in vivo measurements of the fumarase activity non-invasively by hyperpolarized [1,4-C-13] fumarate MR imaging. The combined in vitro and in vivo biomarker of AKI responds to the essential requirements for a new reliable biomarker of AKI.
机译:肾缺血/再灌注损伤(IRI)是急性肾损伤(AKI)的主要原因,目前,由于缺乏常用的方法无法评估单肾IRI,因此缺乏可用于诊断AKI和测量早期进展的可靠生物标志物。富马酸酶将富马酸酯超极化[1,4-C-13(2)]苹果酸转化为[1,4-C-13(2)]苹果酸作为大鼠肿瘤模型和化学诱导的AKI大鼠坏死的量度。在这里,我们显示与坏死相关的细胞膜降解导致血浆和尿液中富马酸酶活性升高,其次,再灌注后24小时,超极化的[1,4-C-13(2)]苹果酸产生与肾脏坏死相关。 40分钟单侧缺血大鼠模型。对生物流体进行富马酸酯酶活性筛选可以检测双侧和单侧AKI模型中的损伤严重程度,从而区分中度和重度AKI以及短期和长期AKI。此外,在通过生物流体分析验证了肾脏损伤后,可以通过富极化[1,4-C-13]富马酸盐MR成像非侵入性地体内测量富马酸酶活性来监测精确的损伤位置。 AKI的体外和体内生物标志物结合在一起,可以满足AKI新型可靠生物标志物的基本要求。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号